Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib and capecitabine in HER2+ metastatic colorectal cancer
NCT04227041Phase 2Unknown
- Sponsor
- Qingdao Zhixin Health Technology
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in colorectal cancer (CRC), sponsored by Qingdao Zhixin Health Technology. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04227041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04227041.